Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens

OncoImmunology

Volumn 2, Issue 7, 2013, Pages

  Aruga, Atsushi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Biliary tract cancer; Cancer vaccine; Cancer testis antigen; Immunotherapy; Peptide vaccine

Indexed keywords

ABECOMOTIDE; CANCER TESTIS ANTIGEN; CANCER VACCINE; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; DEP DOMAIN CONTAINING 1; FREUND ADJUVANT; GLUTAMINYLTYROSYLTYROSYLGLUTAMINYLLEUCYLPHENYLALANYLVALYLASPARAGINYLISOLEUCINE; INSULIN LIKE GROWTH FACTOR 2 MESSENGER RNA BINDING PROTEIN 3; LYMPHOCYTE ANTIGEN 6 COMPLEX LOCUS K; POLYPEPTIDE; PROTEIN KINASE; SERYLTYRSOYLARAGINYLASPARAGINYLGLUTAMYLISOLEUCYLALANYLLEUCINE; TANURMOTIDE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN PRESENTATION; ARTICLE; BILIARY TRACT CANCER; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; GALLBLADDER CANCER; HUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84886945645     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24882     Document Type: Article

References (10)

1. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103:469-74; PMID:20628385; http:// dx.doi.org/10.1038/sj.bjc.6605779
2. Matsushita N, Aruga A, Inoue Y, Kotera Y, Takeda K, Yamamoto M. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Oncol Rep 2013; 29:951-9; PMID:23314271
3. Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, et al. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer. Clin Cancer Res 2013; 19:2224-31; PMID:23479678; http://dx.doi.org/10.1158/1078-0432.CCR-12-3592
4. Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012; 10:141; PMID:22776426; http://dx.doi.org/10.1186/1479-5876-10-141
5. Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, et al. Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol 2012; 42:591-600; PMID:22636067; http://dx.doi.org/10.1093/jjco/ hys069
6. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18:3686-96; PMID:22577059; http:// dx.doi.org/10.1158/1078-0432.CCR-11-3044
7. Okuno K, Sugiura F, Hida JI, Tokoro T, Ishimaru E, Sukegawa Y, et al. Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med 2011; 2:73- 9; PMID:22977472
8. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10:1; PMID:22214470; http://dx.doi. org/10.1186/1479-5876-10-1
9. Ogi C, Aruga A. Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother 2013; 9:1- 9; http://dx.doi.org/10.4161/hv.23917
10. Shimizu K, Kotera Y, Aruga A, Takeshita N, Takasaki K, Yamamoto M. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2012; 19:171-8; PMID:21874278; http://dx.doi.org/10.1007/s00534- 011-0437-y